Protalix BioTherapeutics Inc. | Ownership
Companies that own Protalix BioTherapeutics Inc.
Opaleye Management, Inc.
3,100,000
2.13%
-160,000
0.38%
06/30/2018
Renaissance Technologies LLC
2,614,700
1.8%
305,200
0%
06/30/2018
IBI Mutual Funds Management (1978) Ltd.
1,089,874
0.75%
727
0.13%
06/28/2018
The California Public Employees Retirement System
800,900
0.55%
0
0%
06/30/2018
Barometer Investment House Ltd.
530,243
0.36%
-5,878
0.28%
06/28/2018
Apo Asset Management GmbH
489,500
0.34%
346,500
0.01%
06/29/2018
Migdal Mutual Funds Ltd.
406,184
0.28%
8,721
0.01%
06/28/2018
Maor Luski Investment House Ltd.
300,428
0.21%
109,886
3.54%
05/31/2018
SG Americas Securities LLC
225,000
0.16%
0
0%
06/30/2018
Lamashkia Mutual Funds Management Co. (1982) Ltd.
223,863
0.15%
70,109
0.12%
05/31/2018
| Address |
2 Snunit Street
Carmiel HZ 21614
Israel
|
|
Employees
|
- |
| Website |
http://www.protalix.com |
| Updated |
07/08/2019 |
| Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system. It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease. The company's drugs also include Oral Glucocerebrosidase for potential treatment of Gaucher disease; therapeutic proteins for Fabry disease, and immune diseases such as rheumatoid, psoriatic and juvenile idiopathic arthritis, ankylosing, spondylitis, and plaque psoriasis; and protein for biodefense and other indications. |
